These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 34629893)

  • 1. Efficacy of a Nasal Spray Containing Iota-Carrageenan in the Postexposure Prophylaxis of COVID-19 in Hospital Personnel Dedicated to Patients Care with COVID-19 Disease.
    Figueroa JM; Lombardo ME; Dogliotti A; Flynn LP; Giugliano R; Simonelli G; Valentini R; Ramos A; Romano P; Marcote M; Michelini A; Salvado A; Sykora E; Kniz C; Kobelinsky M; Salzberg DM; Jerusalinsky D; Uchitel O
    Int J Gen Med; 2021; 14():6277-6286. PubMed ID: 34629893
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A study protocol for a double-blind randomised placebo-controlled trial evaluating the efficacy of carrageenan nasal and throat spray for COVID-19 prophylaxis-ICE-COVID.
    Jessop ZM; Gibson J; Lim JY; Jovic TH; Combellack E; Dobbs TD; Carter K; Hiles S; Islam S; Healy B; Humphreys I; Eccles R; Hutchings HA; Whitaker IS
    Trials; 2022 Sep; 23(1):782. PubMed ID: 36109791
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lessons learned from a double-blind randomised placebo-controlled study with a iota-carrageenan nasal spray as medical device in children with acute symptoms of common cold.
    Fazekas T; Eickhoff P; Pruckner N; Vollnhofer G; Fischmeister G; Diakos C; Rauch M; Verdianz M; Zoubek A; Gadner H; Lion T
    BMC Complement Altern Med; 2012 Sep; 12():147. PubMed ID: 22950667
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pre-exposure prophylaxis with hydroxychloroquine for high-risk healthcare workers during the COVID-19 pandemic: A structured summary of a study protocol for a multicentre, double-blind randomized controlled trial.
    Grau-Pujol B; Camprubí D; Marti-Soler H; Fernández-Pardos M; Guinovart C; Muñoz J
    Trials; 2020 Jul; 21(1):688. PubMed ID: 32727613
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of an antiviral Iota-Carrageenan nasal spray: a randomized, double-blind, placebo-controlled exploratory study in volunteers with early symptoms of the common cold.
    Eccles R; Meier C; Jawad M; Weinmüllner R; Grassauer A; Prieschl-Grassauer E
    Respir Res; 2010 Aug; 11(1):108. PubMed ID: 20696083
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of iota-carrageenan nasal spray versus placebo in early treatment of the common cold in adults: the ICICC trial.
    Eccles R; Winther B; Johnston SL; Robinson P; Trampisch M; Koelsch S
    Respir Res; 2015 Oct; 16():121. PubMed ID: 26438038
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of a carrageenan nasal spray in patients with common cold: a randomized controlled trial.
    Ludwig M; Enzenhofer E; Schneider S; Rauch M; Bodenteich A; Neumann K; Prieschl-Grassauer E; Grassauer A; Lion T; Mueller CA
    Respir Res; 2013 Nov; 14(1):124. PubMed ID: 24219370
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Carrageenan nasal spray in virus confirmed common cold: individual patient data analysis of two randomized controlled trials.
    Koenighofer M; Lion T; Bodenteich A; Prieschl-Grassauer E; Grassauer A; Unger H; Mueller CA; Fazekas T
    Multidiscip Respir Med; 2014; 9(1):57. PubMed ID: 25411637
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reconvalescent plasma/camostat mesylate in early SARS-CoV-2 Q-PCR positive high-risk individuals (RES-Q-HR): a structured summary of a study protocol for a randomized controlled trial.
    Keitel V; Jensen B; Feldt T; Fischer JC; Bode JG; Matuschek C; Bölke E; Budach W; Plettenberg C; Scheckenbach K; Kindgen-Milles D; Timm J; Müller L; Kolbe H; Stöhr A; Calles C; Hippe A; Verde P; Spinner CD; Schneider J; Wolf T; Kern WV; Nattermann J; Zoufaly A; Ohmann C; Luedde T;
    Trials; 2021 May; 22(1):343. PubMed ID: 34001215
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized multicenter clinical trial to evaluate the efficacy of melatonin in the prophylaxis of SARS-CoV-2 infection in high-risk contacts (MeCOVID Trial): A structured summary of a study protocol for a randomised controlled trial.
    García IG; Rodriguez-Rubio M; Mariblanca AR; de Soto LM; García LD; Villatoro JM; Parada JQ; Meseguer ES; Rosales MJ; González J; Arribas JR; Carcas AJ; de la Oliva P; Borobia AM
    Trials; 2020 Jun; 21(1):466. PubMed ID: 32493475
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Controlled, double-blind, randomized trial to assess the efficacy and safety of hydroxychloroquine chemoprophylaxis in SARS CoV2 infection in healthcare personnel in the hospital setting: A structured summary of a study protocol for a randomised controlled trial.
    Cuadrado-Lavín A; Olmos JM; Cifrian JM; Gimenez T; Gandarillas MA; García-Saiz M; Rebollo MH; Martínez-Taboada V; López-Hoyos M; Fariñas MC; Crespo J
    Trials; 2020 Jun; 21(1):472. PubMed ID: 32493494
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Iota-carrageenan and xylitol inhibit SARS-CoV-2 in Vero cell culture.
    Bansal S; Jonsson CB; Taylor SL; Figueroa JM; Dugour AV; Palacios C; Vega JC
    PLoS One; 2021; 16(11):e0259943. PubMed ID: 34797868
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of iota-carrageenan nasal spray in treatment and prevention of the common cold.
    Bichiri D; Rente AR; Jesus Â
    Med Pharm Rep; 2021 Jan; 94(1):28-34. PubMed ID: 33629045
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of hydroxychloroquine for post-exposure prophylaxis to prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection among adults exposed to coronavirus disease (COVID-19): a structured summary of a study protocol for a randomised controlled trial.
    Barnabas RV; Brown E; Bershteyn A; Miller RS; Wener M; Celum C; Wald A; Chu H; Wesche D; Baeten JM;
    Trials; 2020 Jun; 21(1):475. PubMed ID: 32493478
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
    Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
    Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Safety of Hydroxychloroquine vs Placebo for Pre-exposure SARS-CoV-2 Prophylaxis Among Health Care Workers: A Randomized Clinical Trial.
    Abella BS; Jolkovsky EL; Biney BT; Uspal JE; Hyman MC; Frank I; Hensley SE; Gill S; Vogl DT; Maillard I; Babushok DV; Huang AC; Nasta SD; Walsh JC; Wiletyo EP; Gimotty PA; Milone MC; Amaravadi RK;
    JAMA Intern Med; 2021 Feb; 181(2):195-202. PubMed ID: 33001138
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Virtualized clinical studies to assess the natural history and impact of gut microbiome modulation in non-hospitalized patients with mild to moderate COVID-19 a randomized, open-label, prospective study with a parallel group study evaluating the physiologic effects of KB109 on gut microbiota structure and function: a structured summary of a study protocol for a randomized controlled study.
    Haran JP; Pinero JC; Zheng Y; Palma NA; Wingertzahn M
    Trials; 2021 Apr; 22(1):245. PubMed ID: 33810796
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy assessment of allogeneic human dental pulp stem cells to treat patients with severe COVID-19: structured summary of a study protocol for a randomized controlled trial (Phase I / II).
    Ye Q; Wang H; Xia X; Zhou C; Liu Z; Xia ZE; Zhang Z; Zhao Y; Yehenala J; Wang S; Zhou G; Hu K; Wu B; Wu CT; Wang S; He Y
    Trials; 2020 Jun; 21(1):520. PubMed ID: 32532356
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.